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Abstract
The 2012 ERA-EDTA Registry Annual Report contains both good news and bad news. On the bright
side, the 2-year survival of patients starting renal replacement therapy (RRT) for chronic kidney
disease (CKD), on dialysis or receiving a living-related kidney transplantation, has progressively in-
creased to 82.2, 79.7 and 98.3%, respectively, whereas for cadaveric kidney transplantation it
remains stable (96.0–96.1%). On the dark side, inequalities persist between European citizens in
access to renal transplantation and in incidence and prevalence of RRT. Living in Greece, Belgium
(French- or Dutch-speaking) or Portugal (the GBP countries) is associated with higher chances of
initiating RRT than living in other European countries. The adjusted RRT incidence for GBP countries
was 188, 201-174 and 220* (* unadjusted) pmp in 2012, respectively (versus 122, 114 and 97 pmp
in the Netherlands or two Spanish regions bordering Portugal). In lower income countries, a low
RRT incidence may represent lack of access to needed healthcare (e.g. Montenegro 26 pmp).
However, how can the high incidence and prevalence of RRT in the GBP countries be explained? Do
GBP citizens have access to RRT that is denied, rejected or considered unnecessary in other high
income countries? Does the GBP healthcare system fail to prevent progression of CKD? Do local
genetic or environmental factors favour CKD progression? Unravelling the underlying reasons is an
urgent research need: only an understanding of the causes will allow correction of the problem.
Unavailability of data from some large countries (e.g. Germany and Italy) is not helpful.
Keywords: access to healthcare; chronic kidney disease; dialysis; inequality; mortality
The recent publication of the 2012 ERA-EDTA Registry
Annual Report contains both good news and bad news [1].
On the bright side, survival of patients on renal replace-
ment therapy (RRT) for end-stage chronic kidney disease
(CKD) is progressively increasing as observed when 2012
data are compared with 2011 and 2010 data [1–3]
(Figure 1). On the dark side, the 2012 report shows persist-
ence of inequalities in the incidence and prevalence of
RRT and in access to optimal therapeutic modalities, such
as kidney transplantation, across different European coun-
tries (Figures 2 and 3), that appear to be unexplained by
demography or by per capita gross domestic product
(Figure 4). Three countries, Greece, Belgium and Portugal,
the GBP (pronounced GeeBeeP) countries, top the charts
of incidence and prevalence of RRT one more year. These
differences may point out serious issues with public
health planning, access or provision of predialysis health-
care or access to RRT in Europe—although it is yet unclear
whether the problem lies with the GBPs or the rest of
Europe.
Fig. 1. Two-year survival on RRT. Improving life expectancy in RRT, dialysis
or living donor transplantation (LD), but stabilization in cadaveric donor
transplantation (CD). Source: references [1–3].
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Cautious optimism
The 2-year survival of patients starting RRT has progres-
sively increased for cohorts from 2001 to 2006, measured
either as overall survival for patients starting RRT (to
82.2% for the cohort starting in 2006 reported in the ERA-
EDTA Registry 2012 report), on dialysis (79.7%) or receiving
living-related kidney transplantation (98.3%) (Figure 1)
[1–3]. In contrast, 2-year survival for cadaveric kidney
transplantation remains stable at 96.0–96.1% for cohorts
starting from 2003 to 2006 pointing to a plateau that
would need novel approaches to be surpassed. These data
are in agreement with other registries reporting increas-
ing overall survival of patients starting RRT in the last
decade [4–7]. Similar improvements were observed for
5-year survival, pointing to an overall improvement in the
Fig. 2. Mean 2010–12 adjusted incidence and prevalence data for selected countries and regions. (A) Incidence of RRT, pmp at Day 1 standardized to the
age and gender distribution of the EU27 population. (B) Incidence of RRT, pmarp at Day 1 for those over 75 years of age. 2010–11 non-standardized 2012:
standardized to the age and gender distribution of the EU27 population. (C) Prevalence of RRT, pmp on 31 December, standardized to the age and gender
distribution of the EU27 population. (D) Prevalence of RRT, pmarp on 31 December, for those over 75 years of age. 2010–11 non-standardized 2012:
standardized to the age and gender distribution of the EU27 population. Note the difference in scale between whole population values (A and C) and over
75-year-old values (B and D). Data expressed as mean + SD of years 2010–12. Nd: no data, *unadjusted. Belgium-D: Belgium Dutch-speaking (Flanders),
Belgium-F: Belgium French-speaking (Wallonia). Source: references [1–3].
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standard of care, unlike the US situation in the 1990s, in
which progressive increases in survival at 12 and 24 months
were associated with decreasing survival at 5 years [4, 8].
The factors that contributed to that U.S. drop in longer-term
survival and whether a similar phenomenon occurred
outside this country still need detailed studies, in search
of lessons that might be learned and applied to improve
the current standard of care.
Cause for concern: inequalities
On the dark side, data point to persistent inequalities
between European citizens in incidence and prevalence of
RRT and in access to transplantation. Living in Greece,
Belgium (both French- and Dutch-speaking) or Portugal
(the GBP countries) is associated with higher chances of
initiating RRT than living in other European countries. Very
high incidence of RRT was also reported in Israel and
Georgia in 2012 and in Turkey in 2011 and 2010. The ad-
justed RRT incidence for GBP countries was 188, 201-174
and 220 pmp in 2012, respectively (although Portugal data
are unadjusted). This compares with 122, 114 and 97 pmp
in the Netherlands or Spanish regions (Galicia, Castilla-
Leon) bordering Portugal (Figure 2A). Moreover, these dif-
ferences persist when prevalence is examined (Figure 2C),
although prevalence/incidence values are lower for high in-
cidence countries (Figure 3). That is, higher incidence is not
completely matched by a higher prevalence. One potential
explanation is more stringent patient selection in low inci-
dence countries, although better on-RRTcare may also con-
tribute. In lower income countries, the low incidence of RRT
may represent lack of access to needed healthcare (e.g.
Montenegro 26 pmp). However, how can the high incidence
and prevalence of RRT in the GBP countries be explained?
(Table 1). Some potential explanations are cause of grave
concern whereas there are innocent alternatives. Do GBP
citizens have access to RRT techniques that are denied to
citizens in other high income countries, e.g. adjusted inci-
dence of RRT 100 pmp in Scotland and 77 pmp in Finland?
Does the healthcare system fail to prevent progression of
CKD in the GBP countries? Are there local genetic or envir-
onmental factors that favour progression of CKD and have
not been tackled by public health authorities? Are there
perverse incentives or forces that favour CKD progression or
initiation of RRT? Or it is just a matter of reporting methods
or of nephrologist beliefs regarding the timing of initiation
of RRT when hard evidence is lacking? Unravelling the
underlying reasons for the observed inequalities is an
urgent research need: only when the causes are known can
corrective measures be applied.
Several countries with low incidence and prevalence of
RRT have higher incomes than countries with higher preva-
lence (Figure 4A). The differences do not appear to depend
on a better public health system or success in preventing
CKD progression in those countries with high income. Thus,
some countries with higher income and low RRT incidence
start RRT at a median younger age than countries which
have both lower income and higher incidence of RRT. In
this regard, low overall incidence and prevalence of RRT is
frequently associated with low incidence and prevalence of
RRT in those aged >75 years (Figures 2B, D and 4C). This is
potentially unsettling given that the incidence of RRT in-
creases with age. Thus, the age pattern is consistent with
denial of RRT to the elderly, refusal of RRT by the elderly or
different criteria for indicating conservative treatment
versus RRT in younger or elderly patients in countries with
low RRT incidence. In these high income countries, low
RRT incidence in the elderly does not appear to depend on
Fig. 3. Mean 2010–12 adjusted prevalence/incidence for selected countries and regions. (A) Mean 2010–12 adjusted prevalence/incidence for the whole
RRT population. (B) Mean 2010–12 adjusted prevalence/incidence for patients >75-year-old. Note same scale for both graphs. *unadjusted. Belgium-D:
Belgium Dutch-speaking (Flanders), Belgium-F: Belgium French-speaking (Wallonia). Source: references [1–3].
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economic constraints, as is the case in low income coun-
tries. The low RRT incidence may be based on the genuine
belief that conservative treatment is the best option for
elderly patients with ESRD [9, 10]. In this regard, there is an
urgent need for hard evidence on the relative merits of
conservative treatment versus RRT in the elderly as well as
on the optimal timing of RRT start. If indeed conservative
management has clear advantages, then in some coun-
tries overdialysis might be an issue. In this regard, a recent
survey of nephrologists from 11 European countries dis-
closed very different practices regarding start of RRT in
uncomplicated relatively young (60-year-old) patients: the
estimated glomerular ﬁltration rates (eGFRs) at which RRT
would be started by different nephrologists ranged from 5
to 20 mL/min/1.73 m2 and this was the most important
parameter to initiate RRT in such a patient for a majority of
nephrologists [10]. Obviously, starting at an eGFR of 5 or 20
mL/min/1.73 m2 may have a great impact on the incidence
of RRT. If the same range would be applied to those over 75
years of age (which was not the subject of the study), it
would mean the difference between initiating and never
initiating RRT for a great number of patients. Interestingly,
Fig. 4. Some factors potentially inﬂuencing incidence and prevalence of RRT. (A) Per capita GDP at current prices—US dollars. Source: UNdata 2012 (https://
data.un.org/Data), except for Scotland and Spanish Regions 2013 (http://www.ine.es/en/prensa/np835_en.pdf). Belgium GDP for both Belgium regions.
Differences in income do not appear to explain differences in RRT incidence and prevalence in neighbouring countries or regions, although the very low
income in Montenegro may relate to low RRT prescription. USD: United States dollars. (B) Life expectancy 2010–15. With the exception of low income
Montenegro, the life expectancy is very similar for countries with striking differences in RRT prescription. This does not support the hypothesis that early
death from other (cardiovascular?) causes explains the low RRT incidence and prevalence in high income countries. Source: UNdata (https://data.un.org/
Data). Country, not regional data presented. (C) Median age at start of RRT in the ERA-EDTA Registry 2012 Report versus incidence of RRT in the same
report. In countries with lower RRT incidence, the median age at start of RRT appears to be lower, suggesting that countries with higher RRT incidence
start older patients in RRT and this may contribute to differences in RRT epidemiology between countries. In (C) country-level data are presented for
Belgium. Belgium-D: Belgium Dutch-speaking (Flanders), Belgium-F: Belgium French-speaking (Wallonia).
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nephrologists from countries with a high incidence of RRT
more often believed that starting at a GFR > 10.5 mL/min/
1.73 m2 is always beneﬁcial compared with respondents
from low incidence countries (18 versus 6%). Furthermore,
the target eGFR was higher for nephrologists working at
for-proﬁt centres. This illustrated another potential issue:
hidden incentives in the healthcare system. Further infor-
mation is needed about the GFR at initiation of RRT in dif-
ferent countries as well as on the use of and acceptance by
patients and doctors and outcomes of conservative man-
agement of ESRD in the elderly. The fact that differences in
prevalence are lower than differences in incidence is con-
cordant with prevalence/incidence value data (Figure 3)
and can be interpreted as a high rate of patient loss in
some high incidence countries. Whether these shorter
periods on RRT in some countries with a high incidence of
RRT result in improved patient quality of life and are indeed
appreciated by the patient should be clariﬁed.
There are additional hypotheses potentially explaining
the lower incidence of RRT coupled to a younger mean age
at start of RRT in some high income countries. Patients may
be dying earlier from cardiovascular disease and, thus, not
living long enough to need RRT. However, life expectancy
does not differ much between countries selected for this
commentary, except for low incomeMontenegro (Figure 4B).
Public health may also impact the incidence and prevalence
of CKD and, thus, of ESRD. Factors potentially involved
include the presence of toxins in the environment or food
(i.e. the exposome, as an example, aristolochic nephropa-
thy), over-the-counter medication policies (allowing unre-
stricted access to nephrotoxic drugs) or country-level
policies regarding salt or phosphate content in the diet. In
addition, the healthcare system may also impact, as an
example, whether there is universal unrestricted access to
healthcare or to nephrologists.
Transplantation
Transplantation is the best therapeutic option for most
patients on RRT. However, huge differences in access to
transplantation are observed between European countries.
The percentage of patients on RRT who have a functioning
kidney graft ranges from 7% in Bosnia and Herzegovina to
≥60% in Norway, Finland and Iceland [1].
Black-out
Also worrisome is the fact that RRT epidemiology data
from some countries big and small (e.g. Germany, Ireland,
Hungary and Italy, among others) at the core of Europe are
not available, as it was the case for 2011 and, except for
some parts of Italy, for 2010 [1–3]. This virtual black-out
makes comparison with other European countries difﬁcult
that could improve the standard of care and to detect
pockets of substandard care or endemic CKD hotspots.
In summary, the ERA-EDTA Registry continues to provide
a wealth of data on the epidemiology of RRT. Key points of
this year’s report include (i) the improving outcomes for
patients on RRT, with exception of recipients of cadaveric
donor kidneys, (ii) the persistence of inequalities in RRT in-
cidence and prevalence and transplantation availability in
different European countries that may hide CKD hotspots,
substandard CKD care, overuse of RRT or lack of access to
needed RRT; and (iii) a preoccupying lack of data from key
countries. There is an urgent need to study the factors
underlying the inequalities in RRT incidence and prevalence
and to identify and correct potential substandard care for
some European citizens.
Acknowledgements. Grant support was provided by ISCIII and
FEDER funds PI13/00047, Sociedad Española de Nefrologia,
ISCIII-RETIC REDinREN/RD012/0021, Comunidad de Madrid CIFRA
S2010/BMD-2378. Salary support was provided by Programa
Intensiﬁcación Actividad Investigadora (ISCIII/Agencia Laín-
Entralgo/CM) to A.O.
Conﬂict of interest statement. None declared.
(See related article by Pippias et al. Renal replacement therapy in
Europe: a summary of the 2012 ERA–EDTA Registry Annual
Report. Clin Kidney J (2015) 8: 248–261.)
References
1. Pippias M, Stel VS, Abad Diez JM et al. Renal replacement
therapy in Europe: a summary of the 2012 ERA-EDTA Registry
Annual Report. CKJ 2015; 8: 248–261
2. Noordzij M, Kramer A, Abad Diez JM et al. Renal replacement
therapy in Europe: a summary of the 2011 ERA-EDTA Registry
Annual Report. Clin Kidney J 2014; 7: 227–238
3. Kramer A, Stel VS, Abad Diez JM et al. Renal replacement
therapy in Europe—a summary of the 2010 ERA–EDTA Regis-
try Annual Report. Clin Kidney J 2013; 6: 105–115
4. Ortiz A, Covic A, Fliser D et al. Epidemiology, contributors to,
and clinical trials of mortality risk in chronic kidney failure.
Lancet 2014; 383: 1831–1843
5. Mitsnefes MM, Laskin BL, Dahhou M et al. Mortality risk among
children initially treated with dialysis for end-stage kidney
disease, 1990–2010. JAMA 2013; 309: 1921–1929
6. Steenkamp R, Shaw C, Feest T. UK Renal Registry 15th annual
report: chapter 5 survival and causes of death of UK adult pa-
tients on renal replacement therapy in 2011: national and centre-
speciﬁc analyses.Nephron Clin Pract 2013; 123(Suppl 1): 93–123
7. Roberts MA, Polkinghorne KR, McDonald SP et al. Secular
trends in cardiovascular mortality rates of patients receiving
dialysis compared with the general population. Am J Kidney
Dis 2011; 58: 64–72
8. Collins AJ, Foley RN, Gilbertson DT et al. The state of chronic
kidney disease, ESRD, and morbidity and mortality in the ﬁrst
year of dialysis. Clin J Am Soc Nephrol 2009; 4(Suppl 1): S5–11
9. Tonkin-Crine S, Okamoto I, Leydon GM et al. Understanding by
older patients of dialysis and conservative management for
chronic kidney failure. Am J Kidney Dis 2015; 65: 443–450
10. van de Luijtgaarden MW, Noordzij M, Tomson C et al. Factors
inﬂuencing the decision to start renal replacement therapy:
results of a survey among European nephrologists. Am J
Kidney Dis 2012; 60: 940–948
Received for publication: 27.4.15; Accepted in revised form: 27.4.15
Table 1. Potential causes of differences in RRT incidence and prevalence
Very concerning
Overuse of RRT
Denial of access to RRT
Financial incentives to initiate RRT
Concerning
Different incidence or progression of CKD
Public health system fails to prevent development of CKD
Healthcare system structure or access results in suboptimal CKD care
Different views on the relative value of RRT versus conservative
management of ESRD
Other
Different data reporting methods
Refusal of RRT by an informed population when RRT is offered
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